AGIOS PHARMACEUTICALS INC (AGIO:NASDAQ)
$33.99 0.09 (0.2655%)
Analysed AGIOS PHARMACEUTICALS INC (AGIO:NASDAQ) News Sources
Agios Provides Update on Phase 2 Trial of Tebapivat in Sickle Cell Disease
21-07-2026
yahoo.com
Agios scraps sickle cell drug
21-07-2026
biopharmadive.com
Agios shares tumble after discontinuing sickle cell disease programme following Phase 2 trial (AGIO)
21-07-2026
advfn.com
Why Is AGIO Stock Falling Today?
21-07-2026
stocktwits.com
Agios scraps sickle cell drug programme on underwhelming Phase II data
21-07-2026
clinicaltrialsarena.com
Why Agios Pharma, A Novo Rival, Just Pulled A Bearish Move
21-07-2026
yahoo.com
Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
23-07-2026
yahoo.com
Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Beats Revenue Estimates
30-07-2026
yahoo.com
Agios Pharmaceuticals Q2 Earnings Call Highlights
30-07-2026
marketbeat.com
Agios Pharmaceuticals Inc (AGIO) (Q2 2026) Earnings Call Highlights: Strong Mitapivat Revenue ...
30-07-2026
yahoo.com
What is the current price of AGIOS PHARMACEUTICALS INC (AGIO:NASDAQ)?
The current price of AGIOS PHARMACEUTICALS INC (AGIO:NASDAQ) is $33.99.
AGIOS PHARMACEUTICALS INC (AGIO:NASDAQ) absolute price change since previous trading day?
The absolute price change of AGIOS PHARMACEUTICALS INC (AGIO:NASDAQ) since the previous trading day is $0.09.
AGIOS PHARMACEUTICALS INC (AGIO:NASDAQ) percentage price change since previous trading day?
The percentage price change of AGIOS PHARMACEUTICALS INC (AGIO:NASDAQ) since the previous trading day is 0.2655%.
What is the most recent average sentiment score for AGIOS PHARMACEUTICALS INC (AGIO:NASDAQ)?
The most recent average sentiment score for AGIOS PHARMACEUTICALS INC (AGIO:NASDAQ) is 57 out of 100.
What is the most recent average sentiment for AGIOS PHARMACEUTICALS INC (AGIO:NASDAQ)?
The most recent sentiment for AGIOS PHARMACEUTICALS INC (AGIO:NASDAQ) is .
SEC-8K** Filing Available For AGIOS PHARMACEUTICALS INC (AGIO:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.